Abstract Number: 1827 • ACR Convergence 2022
The Updated Cardiovascular Risk Tool SCORE2 Provides No Advantage in Identifying Patients with Gout and Carotid Atheroma Plaques
Background/Purpose: Standard cardiovascular (CV) risk assessment tool (SCORE, Framingham Heart Study) performed inaccurately in patients with gout and carotid atheroma plaques (thus, at high CV…Abstract Number: 1828 • ACR Convergence 2022
Urate-lowering Therapy Reduces Non-Episodic Foot Pain in Patients Who Fail to Meet ACR/EULAR 2015 Gout Classification Criteria: An Effect Predicted by Ultrasound
Background/Purpose: Emerging evidence that joints of asymptomatic hyperuricaemic individuals contain monosodium urate (MSU) deposits and that alternative presentations of foot pain occur in hyperuricaemia suggests…Abstract Number: 1829 • ACR Convergence 2022
Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study
Background/Purpose: Urate lowering therapy (ULT) is a cornerstone in the treatment of gout, which afflicts over 2 million individuals with chronic kidney disease (CKD) in…Abstract Number: 1889 • ACR Convergence 2022
Investigating a Possible Bi-Directional Causal Relationship Between Gout and Osteoarthritis for the European Population: Two-Sampled Mendelian Randomization Analysis Study
Background/Purpose: Gout is the most common inflammatory arthritis, and osteoarthritis is the leading cause of arthritis globally. Gout and osteoarthritis frequently coexist in the same…Abstract Number: L05 • ACR Convergence 2021
Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia
Background/Purpose: Gout can be effectively managed by inhibiting synthesis of uric acid. Tigulixostat is a novel non-purine selective xanthine oxidase inhibitor which lowers production of…Abstract Number: L06 • ACR Convergence 2021
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach
Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy (ULT) has been questioned.…Abstract Number: 0177 • ACR Convergence 2021
Dual-Energy Computed Tomography Three Material Decomposition Improves the Sensitivity of Gout Detection
Background/Purpose: Gout, a curable musculoskeletal disease, is characterized by the deposition and accumulation of monosodium urate (MSU) crystals within affected joints. Dual-energy computed tomography (DECT),…Abstract Number: 0467 • ACR Convergence 2021
Assessing the Extent of Lumbosacral Spinal Urate Deposition in Patients with Tophaceous and Nontophaceous Gout Compared with Non-gout Controls Using Dual-Energy CT (DECT)
Background/Purpose: Axial gout involvement was first reported in 1950 (1). Over 100 cases have subsequently been published. Reported cases have presented as acute back pain,…Abstract Number: 0578 • ACR Convergence 2021
Hyperinsulinemic Diet and Increased Risk of Female Gout: 2 Prospective Cohort Studies of US Women over 30 Years
Background/Purpose: Gout and the metabolic (insulin resistance) syndrome frequently coexist. Intravenous insulin has been shown to raise serum urate (SU) levels in physiologic studies1 and…Abstract Number: 0580 • ACR Convergence 2021
Association Between Female Reproductive Factors and Gout: A Nationwide Population-based Cohort Study of 1 Million Postmenopausal Women
Background/Purpose: Previous studies have shown that the incidence and risk factors of gout differs according to sex. However, little research has been done on the…Abstract Number: 0582 • ACR Convergence 2021
Altered Risk of Gout According to Change of Metabolic Parameters in Young Adults
Background/Purpose: Previous studies have shown a link between gout and metabolic syndrome (MetS). It is well known that lifestyle modifications such as weight reduction and…Abstract Number: 0660 • ACR Convergence 2021
Improving the Gout Flare Chart Review Using Linked Claims-EHR Data
Background/Purpose: Recurrent gout flares are the most crucial outcome in studies of gout treatment. However, gout flares is challenging to identify in a large population…Abstract Number: 0661 • ACR Convergence 2021
Effect of Omega-three Supplementation on Serum Urate and Gout Flares in People with Gout; A Pilot Randomized Trial
Background/Purpose: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), also known as omega-3 fats act as alternate COX substrates to arachidonic acid (AA). Their metabolism results…Abstract Number: 0662 • ACR Convergence 2021
Serum Urate Reduction Is Causally Associated with Flare Outcomes in People with Gout: Evidence for Surrogate Status from a Pooled Analysis of 2 Randomized Trials
Background/Purpose: Use of serum urate (SU) as a treatment target and outcome measure has become controversial in light of the American College of Physician Gout…Abstract Number: 0663 • ACR Convergence 2021
Disappearing Digits: A National Retrospective Matched Cohort Study Examining the Risk of Lower Extremity Amputation in Gout
Background/Purpose: Gout is associated with a number of comorbidities such as diabetes that are known risk factors for peripheral vascular disease. These comorbidities along with…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 83
- Next Page »
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 83
- Next Page »
Didn't find what you were looking for? Try the Advanced Search »